



Senvelgo® diabetic consult checklist:

First two weeks of treatment

During the first two weeks of Senvelgo® treatment, ketone testing should be performed every 1-3 days (e.g. via urine dipsticks at home) and immediately if the cat becomes unwell.

Plan for a revisit on day 7 and day 14 of treatment and immediately if any health concerns. For longer-term monitoring a recheck is required at 4 weeks, then every 3 months – there's a separate checklist for this.

History:

Is the cat well? Consider:

- ☐ appetite
- ☐ thirst
- ☐ urination
- ☐ signs of lethargy
- ☐ vomiting
- ☐ diarrhoea

Also check:

- ☐ Senvelgo® administered as prescribed
- ☐ Ketone check every 1-3 days
- ☐ Any questions/general concerns

Nutrition:

- ☐ Appropriate diet/volume

Note: we do not recommend changing their diet during the first two weeks of treatment.

Physical examination:

- ☐ Physical examination
- ☐ Weight/body condition score
- ☐ Hydration

Tests:

- ☐ Ketones
- ☐ Reassess whether tests for concomitant disease required

Owner checklist:

Items:

Senvelgo® prescribed

- ☐ 12 ml bottle (ideal for new cases)
- ☐ 30 ml bottle
- ☐ Urine dipsticks +/- non-absorbable litter
- ☐ Senvelgo® owner leaflet (includes a 14-day owner health record page and a table predicting how long a bottle will last)

Skills/knowledge:

- ☐ Administration technique
- ☐ Ketone testing
- ☐ Plan next appointment
- ☐ Understand importance of contacting vet if cat becomes unwell



Boehringer
Ingelheim

Guidance notes:

Senvelgo® should be administered once daily, at approximately the same time, either directly into the cat's mouth or via a small amount of food to ensure the entire dose is taken at once.

If the cat becomes ketonuric, unwell or has significant weight loss* then suspend Senvelgo® treatment and investigate for underlying disease and treat appropriately.

If diabetic ketoacidosis (DKA) is suspected, stop treatment with Senvelgo® and treat the DKA as per standard protocols, including soluble insulin, intravenous fluid therapy and supplement with glucose/dextrose if blood glucose <15 mmol/l. Please be aware that cats on Senvelgo® may present with normal blood glucose levels, known as euglycaemic DKA (eDKA), but treatment principles remain the same.

Senvelgo® vet website:

To learn more about Senvelgo® and to download the Vet Management Guide (which includes a patient selection and treatment flowchart) and owner leaflets, visit the product vet website:


GB: senvelgo.co.uk IE/Northern Ireland: senvelgo.vet

Note: live chat service available on the 'Veterinary Support' page.

To speak to one of our technical vets call our Vet Diabetes Helpline on:

UK: [01344 746 957](tel:01344746957) IE: [01 291 3985](tel:012913985)

Or email: vetenquiries@boehringer-ingelheim.com



*One study found that >8% loss in body weight in the first 2 weeks of treatment was a risk factor for DKA.¹

1. Behrend, E. N. et al. (2024) Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study. JAVMA 262, 1343-1353.

Senvelgo® contains velagliflozin (sodium-glucose co-transporter 2 [SGLT-2] inhibitor). UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. Senvelgo® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2025 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Sep 2025. UI-PET-0254-2025.

Use Medicines Responsibly.

Prescription decisions are for the person issuing the prescription alone.